During the past decade, Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 8 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 23 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Associazione Italiana Ematologia Oncologia Pediatrica" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia" #1 collaborator was "Biogen" with 1 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator, "Fondazione Adecco per le Pari Opportunità" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Pharmacyclics LLC." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia" are "Chronic Lymphocytic Leukemia" (6 trials), "Leukemia" (4 trials), "Acute Lymphoblastic Leukemia" (3 trials), "Multiple Myeloma" (3 trials) and "Myelodysplastic Syndrome" (3 trials). Many other conditions were trialed in "Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia" in a lesser frequency.

Most popular intervention types in "Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia" are "Drug" (27 trials), "Other" (4 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (3 trials), "Bortezomib" (2 trials), "Eltrombopag" (2 trials), "Ibrutinib" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia" are 36 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 29 completed trials in Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, 3 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".